Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2004-06-30
2006-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Does breast cancer respond to Ispinesib?
2. What are the side effects of Ispinesib?
3. How much Ispinesib is in the blood at specific times after it is taken?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Ispinesib in Metastatic Breast Cancer
NCT00607841
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
NCT00072852
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
NCT00051103
Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
NCT00045188
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
NCT00593827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SB-715992
Females with advanced or metastatic breast cancer were administered Ispinesib
Ispinesib
Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ispinesib
Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously received anthracycline and taxane therapy
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Chapel Hill, North Carolina, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Bandar Tun Razak, Cheras, , Malaysia
GSK Investigational Site
Bandar Tun Razak, Cheras, , Malaysia
GSK Investigational Site
Singapore, , Singapore
GSK Investigational Site
Singapore, , Singapore
GSK Investigational Site
Southampton, Hampshire, United Kingdom
GSK Investigational Site
Manchester, Lancashire, United Kingdom
GSK Investigational Site
Newcastle upon Tyne, Northumberland, United Kingdom
GSK Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KSP20001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.